Product Name :
JNJ-47965567
Description:
JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.
CAS:
1428327-31-4
Molecular Weight:
488.64
Formula:
C28H32N4O2S
Chemical Name:
N-{[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl}-2-(phenylsulfanyl)pyridine-3-carboxamide
Smiles :
O=C(NCC1(CCOCC1)N1CCN(CC1)C1C=CC=CC=1)C1=CC=CN=C1SC1C=CC=CC=1
InChiKey:
XREFXUCWSYMIOG-UHFFFAOYSA-N
InChi :
InChI=1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Venetoclax} web|{Venetoclax} Autophagy|{Venetoclax} Protocol|{Venetoclax} Purity|{Venetoclax} custom synthesis|{Venetoclax} Cancer}
Shelf Life:
≥12 months if stored properly.{{Bexarotene} web|{Bexarotene} RAR/RXR|{Bexarotene} Purity & Documentation|{Bexarotene} In stock|{Bexarotene} supplier|{Bexarotene} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.|Product information|CAS Number: 1428327-31-4|Molecular Weight: 488.64|Formula: C28H32N4O2S|Chemical Name: N-{[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl}-2-(phenylsulfanyl)pyridine-3-carboxamide|Smiles: O=C(NCC1(CCOCC1)N1CCN(CC1)C1C=CC=CC=1)C1=CC=CN=C1SC1C=CC=CC=1|InChiKey: XREFXUCWSYMIOG-UHFFFAOYSA-N|InChi: InChI=1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (204.PMID:25105126 65 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|JNJ-47965567 exhibits high affinity for human and rat P2X7 in membrane preparations of 1321N1 cells. JNJ-47965567 does not block IL-6 and TNF-α release, under identical conditions (LPS and BZ-ATP) used for IL-1β and IL-18 release. JNJ-47965567 attenuates IL-1β release with pIC50s of 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia), respectively, in native systems.|In Vivo:|JNJ-47965567 (30-100 mg/kg; s.c.) attenuates IL-1β release induced by Bz-ATP. JNJ-47965567 (30 mg/kg) attenuates amphetamine-induced hyperactivity and exhibits modest, yet significant efficacy in the rat model of neuropathic pain.|Products are for research use only. Not for human use.|